Short answer: No peptide is FDA approved for gut healing. BPC-157 has many rat studies, and its only colitis trial in people (53 patients, two weeks of enemas) exists only as a 2005 meeting abstract that FDA judged too thin to show it works. KPV has mouse data and no human studies. The gut drugs people track most are GLP-1s, whose labels list nausea, diarrhea and constipation.
| Compound | Best evidence | What it shows |
|---|---|---|
| BPC-157 | Small or early human studies | One small ulcerative colitis trial by enema, reported only as a meeting abstract. FDA found no study of BPC-157 by mouth, injection, nose or skin in people with colitis. |
| KPV | Animal or lab studies only | In mice, KPV in drinking water reduced chemically induced colitis. FDA found no human studies and no human exposure data. |
| Semaglutide (Wegovy) | Approved for a different use | Approved for weight management, not gut health. On the label, nausea hit 44% vs 16% on placebo, and 4.3% stopped because of stomach side effects. |
| Tirzepatide (Zepbound) | Approved for a different use | Approved for weight management, not gut health. Nausea was 25% to 29% across doses vs 8% on placebo on the label. |
"Animal or lab studies only" means no published human trial for this goal that we could find. Results in rats or cells often do not carry over to people. Compounds that are not FDA-approved have no tested label for dose, purity or safety.
BPC-157 was first studied as an anti-ulcer agent. Its developers, a research group in Zagreb, have published many rat studies on stomach ulcers, colitis and fistulas (abnormal tunnels between the gut and skin or other organs). Their reviews describe healing in rats and call it safe, but these are reviews by the same group, and rats are not people.
The human gut evidence, as laid out by FDA in its 2026 review:
FDA concluded there is a lack of evidence to support BPC-157 for ulcerative colitis, and that two weeks of data cannot speak to a disease that often needs years of treatment. Several FDA-approved drugs already treat ulcerative colitis.
KPV is a three-amino-acid piece (lysine, proline, valine) from the end of a hormone called alpha-MSH. In a 2008 study, KPV calmed inflammation signals in human gut cells in a dish, and when added to drinking water it reduced two kinds of chemically induced colitis in mice. It enters gut cells through a transporter called PepT1, which is more active in inflamed colon.
That is where the evidence stops. In its July 2026 review, FDA found no clinical studies of KPV in humans, no human pharmacokinetic data, and no case reports. FDA proposed that KPV not be added to the list of substances pharmacies may compound.
If you take a GLP-1 drug, your gut is what you will notice first. These drugs slow stomach emptying. The labels report, in adults with obesity:
| Side effect | Wegovy 2.4 mg | Placebo (Wegovy trials) | Zepbound 5 / 10 / 15 mg | Placebo (Zepbound trials) |
|---|---|---|---|---|
| Nausea | 44% | 16% | 25% / 29% / 28% | 8% |
| Diarrhea | 30% | 16% | 19% / 21% / 23% | 8% |
| Vomiting | 24% | 6% | 8% / 11% / 13% | 2% |
| Constipation | 24% | 11% | 17% / 14% / 11% | 5% |
| Stopped for stomach side effects | 4.3% | 0.7% | 1.9% / 3.3% / 4.3% | 0.5% |
The Wegovy label also warns about pancreatitis and gallbladder disease, says it is not recommended in severe gastroparesis (a very slow stomach), and asks you to tell your care team before surgery or sedation because of a rare risk of inhaling stomach contents. See Wegovy and Zepbound.
Terms on this page: GLP-1 receptor agonist · Titration (dose escalation) · Peptide · Research use only (RUO)